← Back to Search

Other

AMG 256 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called AMG 256 in adults to see if it is safe and to find the best dose for future studies.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Expansion Phase: Group 2Experimental Treatment1 Intervention
Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
Group II: Dose Expansion Phase: Group 1Experimental Treatment1 Intervention
Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
Group III: Dose Escalation PhaseExperimental Treatment1 Intervention
Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 256
2020
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,433 Previous Clinical Trials
1,395,108 Total Patients Enrolled
MDStudy DirectorAmgen
971 Previous Clinical Trials
939,280 Total Patients Enrolled

Media Library

AMG 256 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04362748 — Phase 1
Solid Tumors Research Study Groups: Dose Escalation Phase, Dose Expansion Phase: Group 1, Dose Expansion Phase: Group 2
Solid Tumors Clinical Trial 2023: AMG 256 Highlights & Side Effects. Trial Name: NCT04362748 — Phase 1
AMG 256 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04362748 — Phase 1
~7 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top